Genes that both extend life and protect against cancer identified

Key points
- A person is 100 times more likely to get cancer at age 65 than at age 35.
- Many of the worm genes have counterparts in humans, suggesting that new drugs may some day ensure a long, cancer-free life.
- The studies are by scientists at the University of California, San Francisco, who say the research also underscores the deep evolutionary connection between lifespan and cancer.
- The worms, known formally as Caenorhabditis elegans, were the stars of a startling 1993 discovery by UCSF biologist Cynthia Kenyon, PhD.
A person is 100 times more likely to get cancer at age 65 than at age 35. But new research reported today in the journal “Nature Genetics” identifies naturally occurring processes that allow many genes to both slow aging and protect against cancer in the much-studied C. elegans roundworm.
Many of the worm genes have counterparts in humans, suggesting that new drugs may some day ensure a long, cancer-free life. The new research and a related study the scientists reported in “Science” last year indicate that cellular changes leading to longevity antagonize tumor cell growth.
The studies are by scientists at the University of California, San Francisco, who say the research also underscores the deep evolutionary connection between lifespan and cancer.
The worms, known formally as Caenorhabditis elegans, were the stars of a startling 1993 discovery by UCSF biologist Cynthia Kenyon, PhD. She found then that a change in just one gene, called daf-2, doubled the worms’ lifespan. This finding led to the understanding that lifespan is regulated by genes and is therefore changeable, rather than the inevitable result of the body’s breakdown. The discovery in worms has been confirmed in other animals including mice.
The new research by Kenyon and graduate student Julie Pinkston is reported in the advanced online edition of the journal.
Kenyon is the American Cancer Society Professor and director of the Hillblom Center for the Biology of Aging at UCSF.
“This is very exciting,” Kenyon said. “There is a widely held view that any mechanism that slows aging would probably stimulate tumor growth. But we found many genes that increase lifespan, but slow tumor growth. Humans have versions of many of these genes, so this work may lead to treatments that keep us youthful and cancer-free much longer than normal.”
Since her early finding that the gene daf-2 and another gene known as daf-16 regulate lifespan, Kenyon’s research team has hoped to identify the genes that they in turn affect - those that more directly affect aging and tumor growth.
“Now we are really getting there,” Kenyon said.
The gene daf-2 codes for a receptor for insulin and also for an insulin-like protein that promotes growth. It influences daf-16, which makes a so-called transcription factor – a protein that determines when and where hundreds of other genes are turned on. The focus of the new study was to identify specific genes regulated by daf-16 which affect cancer and/or lifespan.
The scientists used an established tumor model in the worms. Then, starting with a list of 734 genes known to be targets of daf-16, they identified 29 genes that either promote or suppress tumor cell growth. They did this using several techniques, including RNA interference or RNAi, a powerful tool that allows scientists to control the expression of just one kind of gene at a time.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsMultivitamins with minerals may protect older women with invasive breast cancer
Findings from a study involving thousands of postmenopausal women suggest that women who develop invasive breast cancer may benefit from taking supplements containing both multivitamins and minerals. The new research,…
10 October 2013
NewsAbiraterone acetate delays quality of life decline in men with metastatic prostate cancer
Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in…
25 September 2013
NewsRadiotherapy in Girls and the Risk of Breast Cancer Later in Life
Exposing young women and girls under the age of 20 to ionizing radiation can substantially raise the risk of their developing breast cancer later in life. Scientists may now know why. A collaborative study, in which…





